Research Use Only - Not for human consumption. 18+ only.

Goal Guide · 2026

Best Peptides for Recovery and Healing

Summary

The strongest evidence for recovery and healing points to BPC-157, CJC-1295, and Cerebrolysin. CJC-1295 elevates growth hormone and IGF-1, accelerating tissue repair and improving sleep quality critical to recovery. Cerebrolysin provides neuroprotective and neurotrophic support, showing benefit in stroke and neurological recovery. ACE-031 supports muscle regeneration in wasting conditions. These peptides work through distinct biological pathways, making peptide selection highly dependent on the specific recovery target.

Understanding Recovery and Healing with Peptides

Peptides relevant to recovery and healing generally operate through three core biological mechanisms: stimulating growth hormone and IGF-1 secretion to accelerate tissue synthesis, modulating inflammatory signaling to reduce recovery-limiting inflammation, and activating neurotrophic pathways that support nerve and brain tissue repair. These mechanisms are not mutually exclusive, and some peptides engage multiple pathways simultaneously, which helps explain their broad utility across different recovery contexts including musculoskeletal injury, metabolic stress, and neurological damage.

Growth hormone-releasing peptides and analogs such as CJC-1295 are particularly relevant to physical recovery because growth hormone and IGF-1 are primary drivers of collagen synthesis, muscle protein synthesis, and anabolic repair processes. Separately, neurotrophic peptide preparations like Cerebrolysin address recovery at the neurological level by promoting neuronal survival, synaptic plasticity, and functional restoration following brain injury or stroke. Myostatin inhibitors such as ACE-031 target skeletal muscle specifically, counteracting the catabolic signals that impair muscle regeneration in disease states.

The evidence landscape for recovery-focused peptides is heterogeneous. CJC-1295 holds Grade B evidence based on human clinical data demonstrating sustained GH and IGF-1 elevation, though large randomized controlled trials specifically for injury recovery remain limited. Cerebrolysin carries Grade B evidence supported by multiple controlled trials in stroke and traumatic brain injury populations, with meta-analyses showing statistically significant improvements in neurological outcomes. ACE-031 has shown promising Phase 1 and 2 data in muscular dystrophy but lacks long-term safety data. Researchers continue to refine dosing protocols and patient selection criteria across all categories.

Peptides Ranked by Evidence (77 found)

PeptideEvidence
RetatrutideAGrade ALarge human randomised controlled trials or FDA/major-authority approvedResearch →
SemaglutideAGrade ALarge human randomised controlled trials or FDA/major-authority approvedResearch →
TesamorelinAGrade ALarge human randomised controlled trials or FDA/major-authority approvedResearch →
ACE-031BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
CJC-1295BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
CerebrolysinBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
GHKBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
GHK-CuBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
Glucagon-Like Peptide-2 (GLP-2)BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
Kisspeptin-10BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
N-Acetyl Selank AmidateBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
NA-Semax-AmidateBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
SS-31BGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
SemaxBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
SermorelinBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
ThymalinBGrade BSmaller human trials, observational studies, or approved in 30+ countriesResearch →
Alpha-MSHCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
BPC-157CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
BronchogenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
CJC-1293CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
CardiogenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
CartalaxCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
ChonlutenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
CortagenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
FGLCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
FollistatinCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
GHRP-1CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
GHRP-2CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
GHRP-3CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
GHRP-4CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
GHRP-6CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
IGF-1 DESCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
IGF-1 LR3CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
IpamorelinCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
KPVCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
LL-37CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
LivagenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
MGFCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
MatrixylCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
OvagenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
PEG-MGFCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
Palmitoyl Tetrapeptide-7CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
PancragenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
PinealonCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
ProstamaxCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
Snap-8CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
TB-500CGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
TestagenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
ThymagenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
VesiluteCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
VesugenCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
VilonCGrade CPrimarily animal or in-vitro studies; limited human dataResearch →
5-Amino-1MQDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
AHK-CuDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
AdamaxDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
AdipotideDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
ApelinResearch →
ApigeninResearch →
Collagen Peptide (Hydrolyzed Collagen)Research →
DiacereinResearch →
FOXO4-DRIDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Ginseng Peptide (GS-Peptide)Research →
HumaninDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Lactoferrin-derived Peptides (LfcinB)Research →
LeptinResearch →
MetforminResearch →
MyostatinDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
NAD+Research →
Pal-AHKDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Pal-GHKDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Palmitoyl Dipeptide-6DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Pentadecapeptide BPC 157Research →
Syn-CollDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
TeriparatideResearch →
Tripeptide-29DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
Tripeptide-3DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →
VialoxDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch →

Getting Started

1

Define Your Recovery Target

Recovery and healing encompasses musculoskeletal repair, neurological recovery, and metabolic restoration, each supported by different peptide classes. Research suggests clearly identifying the tissue system involved before evaluating which peptide mechanism is most applicable.

2

Review Evidence Grade and Safety Profile

Peptides with higher evidence grades such as Cerebrolysin for neurological recovery or CJC-1295 for anabolic tissue repair have more robust clinical data to reference. Consulting published clinical trial literature helps contextualize both efficacy signals and known adverse effect profiles for each compound.

3

Consult a Qualified Medical Professional

Research on recovery peptides is conducted under clinical supervision with defined protocols, patient monitoring, and outcome tracking. A licensed physician or specialist familiar with peptide pharmacology is best positioned to evaluate individual suitability based on health status and recovery goals.

Related Side-by-Side Comparisons

Detailed evidence comparisons for the top recovery and healing peptides.

Frequently Asked Questions

How do peptides differ from traditional recovery interventions like NSAIDs or physical therapy?
Unlike NSAIDs, which primarily suppress inflammation as a symptomatic measure, recovery-focused peptides are investigated for their ability to actively stimulate tissue synthesis, growth factor release, and cellular repair mechanisms. Physical therapy addresses biomechanical and functional restoration, while peptides like CJC-1295 target the biochemical environment required for tissue rebuilding. Research suggests these approaches may be complementary rather than mutually exclusive.
Are peptides for recovery suitable for both acute injury and chronic conditions?
Research has explored peptide use in both contexts, though the evidence base differs. Cerebrolysin has been studied most extensively in acute settings such as stroke and traumatic brain injury, where early intervention appears most beneficial. Peptides like CJC-1295 and ACE-031 have been investigated for chronic conditions including age-related muscle loss and muscular dystrophy. The appropriateness of each peptide depends on the condition, its stage, and individual patient factors.
How long does recovery with peptide protocols typically take in research settings?
Study durations for recovery-focused peptides vary considerably by target tissue and peptide class. Cerebrolysin trials in stroke recovery often run 4 to 12 weeks, with neurological improvements assessed at defined intervals. CJC-1295 studies measuring IGF-1 and body composition changes typically span 8 to 12 weeks or longer. Research indicates that recovery timelines are influenced by injury severity, baseline health, and the specific peptide mechanism being engaged.
Can multiple recovery peptides be combined in research protocols?
Some research protocols have explored peptide combinations, particularly stacking growth hormone secretagogues with other anabolic or anti-inflammatory compounds to address multiple recovery pathways simultaneously. However, combining peptides increases the complexity of safety monitoring and makes it harder to attribute specific outcomes to individual compounds. Current evidence for combination protocols in recovery contexts is limited, and most published data reflects single-agent use.

Not sure where to start?

The Goal Finder asks 3 questions and gives you a personalised peptide recommendation ranked by evidence grade.